{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T12:54:55Z","timestamp":1795006495934,"version":"4.9.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bethune-Puai Medical Research Fund","award":["PAYJ-023"],"award-info":[{"award-number":["PAYJ-023"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to assess the efficacy and safety of baricitinib in Takayasu arteritis (TAK) refractory to TNF-\u03b1 inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicentre, single-arm trial between February 2021 and August 2023. Patients with TAK unresponsive to at least 6\u2009months of TNF-\u03b1 inhibitors were treated with baricitinib 4\u2009mg daily for up to 48\u2009weeks, while continuing of immunosuppressants and glucocorticoids. Clinical features, inflammatory parameters, imaging changes and treatment data were collected during follow-up. The primary end point was the overall response (ORR) (complete response [CR] plus partial response [PR]) at 24\u2009weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 10 patients (nine female and one male) patients were enrolled, with median age of 29\u2009years (26.0, 35.3) and a median disease duration of 56.5\u2009months (31.8, 88.5). The ORR at 24\u2009weeks was 80%, with six patients achieving CR and two achieving PR. Disease progression was noted in the remaining two patients. Disease activity, ESR and CRP at 24\u2009weeks were significantly decreased compared with those at baseline. The median glucocorticoid dosage decreased from 20.0\u2009mg\/day (15.0, 26.3) at baseline (P\u2009&amp;lt;\u20090.001) to 6.3\u2009mg\/day (4.4, 10.6) at 24\u2009weeks. No relapse was observed in the eight patients who achieved a response. The adverse effects (AEs) included upper respiratory tract infection (n\u2009=\u20092) and diarrhoea (n\u2009=\u20091), with no serious AEs reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baricitinib is effective in patients with TAK resistant to conventional treatments and anti-TNF-\u03b1 therapy and demonstrates a notable steroid-sparing effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov; NCT06662721.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf286","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T09:42:27Z","timestamp":1747993347000},"page":"5262-5268","source":"Crossref","is-referenced-by-count":5,"title":["Baricitinib for Takayasu arteritis refractory to TNF-\u03b1 inhibitors: a multicentre, single-arm trial"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4073-006X","authenticated-orcid":false,"given":"Jiachen","family":"Li","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University People\u2019s Hospital , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University People\u2019s Hospital , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University People\u2019s Hospital , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shijiazhuang People\u2019s Hospital , Shijiazhuang,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shijiazhuang People\u2019s Hospital , Shijiazhuang,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shijiazhuang People\u2019s Hospital , Shijiazhuang,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shijiazhuang People\u2019s Hospital , Shijiazhuang,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixia","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shijiazhuang People\u2019s Hospital , Shijiazhuang,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Qingdao Women and Children\u2019s Hospital , Qingdao,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Qingdao Women and Children\u2019s Hospital , Qingdao,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Qingdao Women and Children\u2019s Hospital , Qingdao,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglei","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Qingdao Women and Children\u2019s Hospital , Qingdao,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Qingdao Women and Children\u2019s Hospital , Qingdao,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Qingdao Women and Children\u2019s Hospital , Qingdao,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Qingdao Women and Children\u2019s Hospital , Qingdao,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University People\u2019s Hospital , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University People\u2019s Hospital , Beijing,","place":["China"]},{"name":"Department of Rheumatology and Immunology, Qingdao Women and Children\u2019s Hospital , Qingdao,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University People\u2019s Hospital , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Peking University People\u2019s Hospital , Beijing,","place":["China"]},{"name":"Department of Rheumatology and Immunology, Shijiazhuang People\u2019s Hospital , Shijiazhuang,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"2026091216020783300_keaf286-B1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41572-021-00327-5","article-title":"Large-vessel vasculitis","volume":"7","author":"Pugh","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"2026091216020783300_keaf286-B2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/rheumatology\/key040","article-title":"Takayasu arteritis: advanced understanding is leading to new horizons","volume":"58","author":"Tombetti","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2026091216020783300_keaf286-B3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaut.2018.08.001","article-title":"Overall survival and mortality risk factors in Takayasu\u2019s arteritis: a multicenter study of 318 patients","volume":"96","author":"Mirouse","year":"2019","journal-title":"J Autoimmun"},{"key":"2026091216020783300_keaf286-B4","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1161\/circulationaha.116.027094","article-title":"Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients","volume":"136","author":"Comarmond","year":"2017","journal-title":"Circulation"},{"key":"2026091216020783300_keaf286-B5","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the management of giant cell arteritis and Takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026091216020783300_keaf286-B6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1136\/heartjnl-2016-310848","article-title":"Takayasu arteritis: challenges in diagnosis and management","volume":"104","author":"Kim","year":"2018","journal-title":"Heart"},{"key":"2026091216020783300_keaf286-B7","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s00296-021-04958-5","article-title":"Corticosteroid monotherapy for the management of Takayasu arteritis \u2013 a systematic review and meta-analysis","volume":"41","author":"Misra","year":"2021","journal-title":"Rheumatol Int"},{"key":"2026091216020783300_keaf286-B8","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1253\/circj.cj-11-1108","article-title":"Improved prognosis of Takayasu arteritis over the past decade\u2014comprehensive analysis of 106 patients","volume":"76","author":"Ohigashi","year":"2012","journal-title":"Circ J"},{"key":"2026091216020783300_keaf286-B9","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1007\/s10067-021-05743-2","article-title":"Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis \u2013 a systematic review and meta-analysis","volume":"40","author":"Misra","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2026091216020783300_keaf286-B10","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1093\/rheumatology\/keab635","article-title":"Efficacy and safety of TNF-\u03b1 antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients","volume":"61","author":"Mekinian","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026091216020783300_keaf286-B11","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/art.42496","article-title":"Comparative efficacy of secukinumab versus tumor necrosis factor inhibitors for the treatment of takayasu arteritis","volume":"75","author":"Tian","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026091216020783300_keaf286-B12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026091216020783300_keaf286-B13","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK\u2013STAT pathway at 30: much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"key":"2026091216020783300_keaf286-B14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/rai2.12155","article-title":"Inflammasomes and their roles in autoimmune diseases","volume":"4","author":"Pan","year":"2024","journal-title":"Rheumatol Autoimmun"},{"key":"2026091216020783300_keaf286-B15","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"key":"2026091216020783300_keaf286-B16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jaad.2022.10.055","article-title":"JAK inhibitors for the treatment of adult dermatomyositis: a pilot study","volume":"88","author":"Landon-Cardinal","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026091216020783300_keaf286-B17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2478\/rir-2022-0017","article-title":"JAK\/STAT pathway targeting in primary Sj\u00f6gren syndrome","volume":"3","author":"Gandolfo","year":"2022","journal-title":"Rheumatol Immunol Res"},{"key":"2026091216020783300_keaf286-B18","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus kinase family in autoimmune skin diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front Immunol"},{"key":"2026091216020783300_keaf286-B19","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000424","article-title":"Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways","volume":"7","author":"D\u00f6rner","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2026091216020783300_keaf286-B20","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2026091216020783300_keaf286-B21","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/s0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"key":"2026091216020783300_keaf286-B22","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1136\/annrheumdis-2021-221961","article-title":"Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study","volume":"81","author":"Koster","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026091216020783300_keaf286-B23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003985","article-title":"Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre","volume":"10","author":"Zhou","year":"2024","journal-title":"RMD Open"},{"key":"2026091216020783300_keaf286-B24","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/rheumatology\/kex075","article-title":"Are the 1990 American College of Rheumatology vasculitis classification criteria still valid?","volume":"56","author":"Seeliger","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2026091216020783300_keaf286-B25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.7326\/0003-4819-120-11-199406010-00004","article-title":"Takayasu arteritis","volume":"120","author":"Kerr","year":"1994","journal-title":"Ann Intern Med"},{"key":"2026091216020783300_keaf286-B26","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/rheumatology\/ket128","article-title":"Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010)","volume":"52","author":"Misra","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"2026091216020783300_keaf286-B27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/annrheumdis-2021-220832","article-title":"Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study","volume":"81","author":"Kong","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026091216020783300_keaf286-B28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.autrev.2018.01.019","article-title":"Non-glucocorticoid drugs for the treatment of Takayasu\u2019s arteritis: a systematic review and meta-analysis","volume":"17","author":"Barra","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2026091216020783300_keaf286-B29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","article-title":"Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)","volume":"77","author":"Nakaoka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026091216020783300_keaf286-B30","doi-asserted-by":"publisher","first-page":"20406223221131715","DOI":"10.1177\/20406223221131715","article-title":"Tocilizumab for faster and safer remission of Takayasu\u2019s arteritis","volume":"13","author":"Liao","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"2026091216020783300_keaf286-B31","doi-asserted-by":"publisher","first-page":"105658","DOI":"10.1016\/j.jbspin.2023.105658","article-title":"Effectiveness and safety of rituximab in Takayasu arteritis: a multicenter retrospective study","volume":"91","author":"Mekinian","year":"2024","journal-title":"Joint Bone Spine"},{"key":"2026091216020783300_keaf286-B32","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/rheumatology\/kex249","article-title":"Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature","volume":"57","author":"Pazzola","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2026091216020783300_keaf286-B33","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41392-024-01934-w","article-title":"The JAK\u2013STAT pathway: from structural biology to cytokine engineering","volume":"9","author":"Lv","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026091216020783300_keaf286-B34","doi-asserted-by":"publisher","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2026091216020783300_keaf286-B35","doi-asserted-by":"publisher","first-page":"1494901","DOI":"10.3389\/fphar.2024.1494901","article-title":"JAK inhibitors: an evidence-based choice of the most appropriate molecule","volume":"15","author":"Antonioli","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026091216020783300_keaf286-B36","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11926-020-00948-x","article-title":"Pathogenesis of giant cell arteritis and Takayasu arteritis-similarities and differences","volume":"22","author":"Watanabe","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"2026091216020783300_keaf286-B37","doi-asserted-by":"publisher","first-page":"881705","DOI":"10.3389\/fimmu.2022.881705","article-title":"Perspectives of JAK inhibitors for large vessel vasculitis","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front Immunol"},{"key":"2026091216020783300_keaf286-B38","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026091216020783300_keaf286-B39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaut.2019.01.010","article-title":"Autophagy promotes aortic adventitial fibrosis via the IL-6\/Jak1 signaling pathway in Takayasu\u2019s arteritis","volume":"99","author":"Chen","year":"2019","journal-title":"J Autoimmun"},{"key":"2026091216020783300_keaf286-B40","doi-asserted-by":"publisher","first-page":"152018","DOI":"10.1016\/j.semarthrit.2022.152018","article-title":"Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: a prospective study","volume":"55","author":"Wang","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2026091216020783300_keaf286-B41","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1093\/rheumatology\/keaa281","article-title":"Tofacitinib in patients with refractory Takayasu\u2019s arteritis","volume":"59","author":"Li","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026091216020783300_keaf286-B42","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1007\/s10875-023-01483-x","article-title":"JAKs and STATs from a clinical perspective: loss-of-function mutations, gain-of-function mutations, and their multidimensional consequences","volume":"43","author":"Ott","year":"2023","journal-title":"J Clin Immunol"},{"key":"2026091216020783300_keaf286-B43","doi-asserted-by":"publisher","DOI":"10.3390\/cells8090963","article-title":"Signaling pathways of type I and type III interferons and targeted therapies in systemic lupus erythematosus","volume":"8","author":"Chyuan","year":"2019","journal-title":"Cells"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf286\/63329248\/keaf286.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/10\/5262\/63329248\/keaf286.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/10\/5262\/63329248\/keaf286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:02:13Z","timestamp":1789243333000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/10\/5262\/8145578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf286","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,5,24]]}}}